Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial.
Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Ondrej Blaha, Yiwen Liu, Jessica M Stempel, Najla H Al Ali, Amy E DeZern, Mikkael A Sekeres, Geoffrey L Uy, Samuel Urrutia, Hetty E Carraway, Pinkal Desai, Elizabeth A Griffiths, Eytan M Stein, Andrew M Brunner, Christine McMahon, Rory M Shallis, Joshua F Zeidner, Michael R Savona, Hayley Hawkins, Namrata Sonia Chandhok, Constantine Logothetis, Aram Bidikian, Ted M Getz, Gail J Roboz, Benjamin Rolles, Eunice S Wang, Amyah C Harris, Maria L Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw P Maciejewski, David Sallman, Rahul S Vedula, H Moses Murdock, Harrison K Tsai, Evan C Chen, Lionel Ades, R Coleman Lindsley, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S Komrokji, Maximilian Stahl, Amer M Zeidan
Haematologica 10.3324/haematol.2026.301314
摘要
摘要
Response assessment criteria in patients with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) have been updated in the 2023 International Working Group (IWG) criteria. However, validation of these criteria has been limited to date. We analyzed overall survival (OS) by best response according to IWG 2023 criteria in two separate and independent cohorts of patients with HR-MDS who were treated with hypomethylating agents (HMA)-based therapies. The first dataset was the International Consortium for MDS (icMDS) VALIDATE retrospective database, and the second dataset was the cohort of HR-MDS patients treated in the randomized, phase III PANTHER trial of azacitidine + pevonedistat or placebo. A total of 1,268 patients (VALIDATE: n=1,047; PANTHER: n=221) were evaluated in two separate sets of analyses according to the source dataset. Patients who achieved composite CR (cCR) had improved OS compared to patients not achieving cCR in both datasets and in both univariate and multivariable analyses (VALIDATE: multivariable Hazard Ratio [HR]: 0.65; 95% CI: 0.55-0.76; p.
KM 提取结果
0 个 Figure · 0 个 KM 面板